Sergio Iannazzo

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Topics

Myasthenia Gravis

Epidermal Growth Factor Receptor

Chronic Myeloid Leukemia

Top Venues

Advances in therapy

Applied health economics and health policy

PharmacoEconomics

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Cécile van Steen, Lorenzo Celico, Erik Spaepen, Tim Hagenacker, Sven Guenther Meuth, Tobias Ruck, A Gordon Smith, Danielle H Bodicoat, Maria De Francesco, Sergio Iannazzo
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. Advances in therapy 41 (6) (2024)
Cécile van Steen, Lorenzo Celico, Erik Spaepen, Tim Hagenacker, Sven Guenther Meuth, Tobias Ruck, A Gordon Smith, Danielle H Bodicoat, Maria De Francesco, Sergio Iannazzo
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. Advances in therapy (2024)
Cécile van Steen, Lorenzo Celico, Erik Spaepen, Tim Hagenacker, Sven Guenther Meuth, Tobias Ruck, A Gordon Smith, Danielle H Bodicoat, Maria De Francesco, Sergio Iannazzo
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. Advances in therapy 41 (6) (2024)
Cécile van Steen, Lorenzo Celico, Erik Spaepen, Tim Hagenacker, Sven Guenther Meuth, Tobias Ruck, A Gordon Smith, Danielle H Bodicoat, Maria De Francesco, Sergio Iannazzo
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. Advances in therapy 41 (6) (2024)
Cécile van Steen, Lorenzo Celico, Erik Spaepen, Tim Hagenacker, Sven Guenther Meuth, Tobias Ruck, A Gordon Smith, Danielle H Bodicoat, Maria De Francesco, Sergio Iannazzo
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. Advances in therapy 41 (6) (2024)
Carsten Hirt, Sergio Iannazzo, Silvia Chiroli, Lisa J McGarry, Philipp le Coutre, Leif Stenke, Torsten Dahlén, Jeffrey H Lipton
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. Applied health economics and health policy 17 (4) (2020)
Sergio Iannazzo, Ange-Christelle Iliza, Louise Perrault
Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36 (2) (2019)
Moshe Yair Levy, Lisa J McGarry, Hui Huang, Stephanie Lustgarten, Silvia Chiroli, Sergio Iannazzo
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Current medical research and opinion 35 (3) (2018)